164 related articles for article (PubMed ID: 8356675)
1. Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1993 Aug; 25(4):2574. PubMed ID: 8356675
[No Abstract] [Full Text] [Related]
2. Results of a prospective, randomized double-blind study comparing standard vs low-dose OKT3 induction therapy.
Alloway R; Kotb M; Hathaway DK; Gaber LW; Vera SR; Gaber AO
Transplant Proc; 1993 Feb; 25(1 Pt 1):550-2. PubMed ID: 8438410
[No Abstract] [Full Text] [Related]
3. Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1996 Dec; 28(6):3466-7. PubMed ID: 8962349
[No Abstract] [Full Text] [Related]
4. Clinical and renal histologic predictors of long-term outcome after OKT3 therapy for steroid-resistant rejection.
Wiener Y; Nakhleh RE; Kupin WL; Lee M; Escobar FS; Venkat KK; Mozes MF
Transplant Proc; 1995 Feb; 27(1):1014-5. PubMed ID: 7878781
[No Abstract] [Full Text] [Related]
5. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
6. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield CF
Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
[No Abstract] [Full Text] [Related]
7. Pentoxifylline reduces the first-dose reactions following OKT3.
Vincenti FG; Vasconcelos M; Birnbaum JL; Tomlanovich SJ; Amend WJ; Melzer JS; Snyder JP
Transplant Proc; 1993 Apr; 25(2 Suppl 1):57-9. PubMed ID: 8465428
[No Abstract] [Full Text] [Related]
8. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
9. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
10. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity.
Vasquez EM; Fabrega AJ; Pollak R
Transplant Proc; 1995 Feb; 27(1):873-4. PubMed ID: 7879215
[No Abstract] [Full Text] [Related]
11. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
[No Abstract] [Full Text] [Related]
12. Prospective trial of OKT3 for early prophylaxis of rejection in immunologic "high risk" renal transplant recipients: long-term results.
Pomer S; Waldherr R; Möhring K; Kempter F; Wiesel M; Weimer R
Transplant Proc; 1992 Oct; 24(5):1732-3. PubMed ID: 1412815
[No Abstract] [Full Text] [Related]
13. Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection.
Jeffrey RF; Johnson MH; Bamford JM; Giles GR; Brownjohn AM; Will EJ
Transplantation; 1993 Mar; 55(3):677-9. PubMed ID: 8456493
[No Abstract] [Full Text] [Related]
14. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
[No Abstract] [Full Text] [Related]
15. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
[No Abstract] [Full Text] [Related]
16. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
Alamartine E; Bellakoul R; Berthoux F
Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
[No Abstract] [Full Text] [Related]
17. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
[No Abstract] [Full Text] [Related]
18. Proliferation rate of cells in the interstitial infiltrate in acute kidney allograft rejection.
Olsen S; Hansen HE
Transplant Proc; 1996 Feb; 28(1):502-3. PubMed ID: 8644329
[No Abstract] [Full Text] [Related]
19. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus infection during OKT3 treatment for renal allograft rejection.
Morgan JD; Horsburgh T; Simpson A; Donnelly PK; Veitch PS; Bell PR
Transplant Proc; 1992 Dec; 24(6):2634-5. PubMed ID: 1334589
[No Abstract] [Full Text] [Related]
[Next] [New Search]